What Does It Cost to Appoint a Clinician or KOL to a Scientific Advisory Board?
An investor recently asked me a relatively straightforward question:
What is the market rate for appointing a recognised clinician or Key Opinion Leader to a biotech Scientific Advisory Board?
It is a question we are hearing more regularly as emerging biotech and medical technology companies look to strengthen their clinical credibility, inform development programmes and build relationships with investors and the wider scientific community.
However, compensation for these appointments is rarely advertised or reported publicly. The titles used by companies are also inconsistent: “scientific adviser”, “SAB member” and “KOL” can describe very different levels of responsibility.
Rather than offer a speculative figure, we canvassed several people with direct experience of these arrangements. They included practising clinicians, an individual with both clinical and industry experience, a biotechnology company that regularly engages scientific advisers, and an experienced life sciences chairman with private diagnostics and public therapeutics experience.
While this was an informal market exercise rather than a formal compensation survey, there was a reassuring degree of agreement.
Scientific Advisory Board day rates
The feedback suggested the following broad guide:
Approximately £500 for a shorter Scientific Advisory Board meeting lasting two to three hours
£1,500 – £2,000 per day for an established clinical specialist
£2,000 – £3,000 per day for a senior national or international KOL
£2,000 – £4,000 per day where the appointment carries greater responsibility or requires particularly specialist input
More than £4,000 per day for some elite advisers, more commonly seen in the US market
A full-day rate would ordinarily reflect more than attendance at the meeting itself. The adviser may also need to review clinical information, prepare comments, read supporting materials or speak with members of the management team beforehand.
This is one reason why comparing a short quarterly meeting with a full day of scientific and clinical input can be misleading.
What determines the appropriate rate?
The profile and reputation of the clinician will inevitably influence compensation, but this is only part of the picture.
In our conversations, several other variables emerged.
The nature of the contribution
Occasional scientific advice is very different from an ongoing role involving clinical-development strategy, trial design, regulatory planning or detailed document review.
Companies should be clear about whether they want the adviser to react to defined questions or contribute proactively to the direction of the programme.
Time commitment
The number and length of meetings matter, but so does the preparation required between them.
Four short meetings with limited preparation represent a different commitment from six formal meetings, regular calls with executives and the expectation that documents will be reviewed at short notice.
Clinical and regulatory responsibility
An adviser providing broad clinical-development input may carry a different level of responsibility from someone contributing to pharmacovigilance, patient-safety or medico-legal decisions.
The greater the responsibility and potential exposure, the more likely it is that compensation will sit towards the upper end of the range.
Public profile and external activity
Some companies want a recognised name who can provide advice privately. Others expect their KOLs to participate in investor meetings, make introductions, attend conferences or become publicly associated with the business.
That external endorsement can be extremely valuable, but it should not be treated as an incidental part of the role.
Adviser or director?
A seat on a Scientific Advisory Board is not the same as a statutory board appointment.
A formal director carries legal duties and governance responsibilities that an adviser ordinarily does not. Companies should define this distinction clearly and structure both the appointment and compensation accordingly.
Geography and company profile
US-based KOLs can command higher rates than their UK or European counterparts, particularly at the most senior end of the market.
Whether the company is privately owned or publicly listed, its funding position and stage of development can also influence both the level and structure of compensation.
What should companies budget annually?
Day rates provide a useful reference point, but many companies want to establish an ongoing relationship rather than purchase isolated days of advice.
Based on the market feedback, a practical annual budgeting framework could look like this:
Light-touch advisory role: £5,000 – £10,000 plus modest options
This might cover four quarterly meetings, limited preparation and occasional access for defined questions.
Regular Scientific Advisory Board role: £12,000 – £25,000 plus options
This would be more appropriate where the adviser attends four to six meetings, reviews documents, prepares in advance and provides some additional support between meetings.
High-profile, actively involved KOL: £25,000 – £40,000 or more, plus meaningful equity
At this level, the individual may contribute regularly to clinical development, trial design, investor engagement, introductions and the company’s external profile.
For a well-funded biotech seeking a genuine brand-name clinician, a working budget of approximately £20,000 – £30,000 per year in cash, plus an equity component, may provide a sensible starting point.
That figure should then be adjusted according to the actual commitment and responsibilities involved.
What role should equity play?
Share options or another form of equity participation are common considerations, particularly when an adviser is expected to build a meaningful, long-term relationship with an emerging company.
Equity can help align the adviser with the success of the business while preserving cash during the company’s earlier stages. However, it should not be used as a substitute for clearly defining the work required or paying appropriately for substantial time commitments.
The size and structure of any award will depend on factors including the company’s stage, valuation, funding, expected duration of the appointment and the adviser’s importance to the programme.
Companies should take appropriate legal and tax advice when designing these arrangements.
Define the contribution before benchmarking the compensation
The clearest lesson from our conversations was that the title alone tells us very little.
A clinician who attends two meetings each year, an SAB member who regularly reviews scientific materials and an internationally recognised KOL who supports investors, trials and external engagement are performing three distinctly different roles.
Before approaching potential advisers, companies should define:
The scientific or commercial problem the appointment is intended to address
The expected number and duration of meetings
The preparation and document review required
Expectations between formal meetings
Any involvement in trials, regulation or patient safety
Whether investor or external-facing activity is required
Whether the company expects to use the individual’s name publicly
The proposed cash and equity structure
How the relationship and its impact will be reviewed
Once those points are clear, it becomes much easier to identify the right individual and agree compensation that is fair to both parties.
Scientific adviser, SAB member and active KOL should not be treated as interchangeable terms. Define the contribution first—and benchmark the compensation second.
RMG supports biotech, pharmaceutical and medical technology businesses with executive search, board appointments and access to specialist leadership networks across the UK, Europe and US.
